Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Exp Neurol. 2017 Jun 9;295:194–201. doi: 10.1016/j.expneurol.2017.06.014

Fig. 6.

Fig. 6

The systemic injection of CB1 and CB2 receptor antagonists do not block the antinociceptive effects of PNU282987 in the formalin test. CB1 receptor antagonist rimonabant (3 mg/kg, i.p.) and CB2 receptor antagonist SR144S28 (3 mg/kg, i.p.) do not block the antinociceptive effects of PNU282987 (10 mg/kg, s.c.) in both (A) phase I and (B) phase II. Data reflect the mean ± S.E.M. of 6–8 animals for each group. * P < 0.05, significantly different from its corresponding control group.